Effect of SSRI exposure on the proliferation rate and glucose uptake in breast and ovary cancer cell lines

Stapel, Britta; Melzer, Catharina; Ohe, Juliane von der; Hillemanns, Peter; Bleich, Stefan; Kahl, Kai G.; Hass, Ralf

doi:10.1038/s41598-020-80850-9

Cited by 10 publications

(7 citation statements)

References 57 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, a recent meta-analysis by Li et al reviewed 19 studies, finding no causal relationship [ 73 ]. And breast cancer cell line research has shown no significant effect of SSRIs on cell glucose uptake [ 74 ]. Indeed, other work has even suggested that such medications may even be used to positive effect.…”

Section: Introductionmentioning

confidence: 99%

Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions

et al. 2023

View full text Add to dashboard Cite

Exploring the relationship between various neurotransmitters and breast cancer cell growth has revealed their likely centrality to improving breast cancer treatment. Neurotransmitters play a key role in breast cancer biology through their effects on the cell cycle, epithelial mesenchymal transition, angiogenesis, inflammation, the tumor microenvironment and other pathways. Neurotransmitters and their receptors are vital to the initiation, progression and drug resistance of cancer and progress in our biological understanding may point the way to lower-cost and lower-risk antitumor therapeutic strategies. This review discusses multiple neurotransmitters in the context of breast cancer. It also discusses risk factors, repurposing of pharmaceuticals impacting neurotransmitter pathways, and the opportunity for better integrated models that encompass exercise, the intestinal microbiome, and other non-pharmacologic considerations. Neurotransmitters’ role in breast cancer should no longer be ignored; it may appear to complicate the molecular picture but the ubiquity of neurotransmitters and their wide-ranging impacts provide an organizing framework upon which further understanding and progress against breast cancer can be based.

show abstract

Section: Introductionmentioning

confidence: 99%

Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions

et al. 2023

View full text Add to dashboard Cite

show abstract

“…A previous study indicated that use of paroxetine is associated with a substantial increase in breast cancer risk [ 29 ]. A recent study also reported that women with breast and ovarian cancer receiving SSRIs exhibit increased recurrence risks and mortality rates [ 30 ]. Conversely, some SSRIs can induce apoptosis in Burkitt lymphoma cells by triggering calcium flux, tyrosine phosphorylation and reduction of the c-myc and nm23 genes [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Protective Effect of Escitalopram on Hepatocellular Carcinoma by Inducing Autophagy

Chen

Hsu

Chan

et al. 2022

IJMS

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is an aggressive cancer with poor prognosis. Although recent research has indicated that selective serotonin reuptake inhibitors (SSRIs), including escitalopram, have anticancer effects, little is known about the effects of escitalopram on HCC. Methods: Both in vitro and in vivo studies were conducted to verify the potentials of escitalopram on HCC treatment. To explore whether the effects of escitalopram are clinically consistent with laboratory findings, a nationwide population-based cohort study was also adopted to examine the association between escitalopram and HCC risk. Results: As compared with THLE-3 cells, escitalopram significantly inhibited the proliferation of HepG2 and Huh-7 cells. Specifically, escitalopram significantly induced autophagy in HepG2 and Huh-7 cells by increasing the LC3-II/LC3-I ratio and the expression of ATG-3, ATG-5, ATG-7, and Beclin-1 proteins. Moreover, escitalopram significantly inhibited the growth of xenografted Huh-7 cells in SCID mice that were treated with 12.5 mg/kg escitalopram. Accordingly, the risk of HCC was negatively correlated with escitalopram use. Conclusions: These findings provided evidence supporting the therapeutic potential of escitalopram for HCC. Both laboratory and nationwide population-based cohort evidence demonstrated the attenuated effects of escitalopram on HCC.

show abstract

“…We have previously indicated how the multifactorial etiopathogenesis of depression makes not only the diagnosis and treatment of this entity difficult, but also prevention remains complex, and numerous studies must be carried out in order to analyze different preventive interventions in cancer patients to improve the quality of life and reduce the incidence of depression and anxiety associated with this entity. In this sense, numerous studies have shown how psychopharmacological drugs in cancer can have effects on cancer patients at different biological levels and can be another tool for the comprehensive management of these patients (186)(187)(188).…”

Section: D) Psychosocial Interventionsmentioning

confidence: 99%

Understanding the basis of major depressive disorder in oncological patients: Biological links, clinical management, challenges, and lifestyle medicine

et al. 2022

View full text Add to dashboard Cite

In recent years, the incidence of different types of cancer and patient survival have been rising, as well as their prevalence. The increase in survival in recent years exposes the patients to a set of stressful factors such as more rigorous follow-up and more aggressive therapeutic regimens that, added to the diagnosis of the disease itself, cause an increase in the incidence of depressive disorders. These alterations have important consequences for the patients, reducing their average survival and quality of life, and for these reasons, special emphasis has been placed on developing numerous screening tests and early recognition of depressive symptoms. Despite that cancer and major depressive disorder are complex and heterogeneous entities, they also share many critical pathophysiological mechanisms, aiding to explain this complex relationship from a biological perspective. Moreover, a growing body of evidence is supporting the relevant role of lifestyle habits in the prevention and management of both depression and cancer. Therefore, the present study aims to perform a thorough review of the intricate relationship between depression and cancer, with a special focus on its biological links, clinical management, challenges, and the central role of lifestyle medicine as adjunctive and preventive approaches to improve the quality of life of these patients.

show abstract

Effect of SSRI exposure on the proliferation rate and glucose uptake in breast and ovary cancer cell lines

Cited by 10 publications

References 57 publications

Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions

Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions

Protective Effect of Escitalopram on Hepatocellular Carcinoma by Inducing Autophagy

Understanding the basis of major depressive disorder in oncological patients: Biological links, clinical management, challenges, and lifestyle medicine

Contact Info

Product

Resources

About